Clinical trial · Interventional
Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer
NCT07761910CI-TRIAL-00121622recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 16, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260916-000001
Summary
Brief summary (as posted)
Prospective clinical study designed to evaluate damage to the heart after receiving standard of care chemotherapy and radiation therapy for locally advanced Non-Small Cell Lung Cancer (NSCLC).
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cardiotoxicity | — | UNRESOLVED | — |
| Locally Advanced Non-Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| Radiation Therapy | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 18F-Flurpiridaz | Drug | — | UNRESOLVED |
| Coronary CT Angiography (CCTA) | Device | — | UNRESOLVED |
| PET/CT 18F-Flurpiridaz Rest/Stress Test | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- PET/CT 18F-Flurpiridaz Rest/Stress Test
- description
- A two-phase, rest and regadenoson stress evaluated by 18F-Flurpiridaz PET/CT before and 3 months after SOC radiation treatment.
- interventionNames
- Diagnostic Test: PET/CT 18F-Flurpiridaz Rest/Stress Test
- Device: Coronary CT Angiography (CCTA)
- Drug: 18F-Flurpiridaz
Primary outcomes (1)
- measure
- Change of MBF (myocardial blood flow)
- timeFrame
- Pre-radiotherapy and 3 months post-radiotherapy
- description
- Assessed using a two-phase, rest and regadenoson stress evaluated by 18F-Flurpiridaz PET/CT
Secondary outcomes (4)
- measure
- Changes in myocardial blood flow to the cardiac base
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥ 18 at time of consent 2. Ability to provide written informed consent and HIPAA authorization 3. Stage III NSCLC per AJCC 8th edition guideline, confirmed by pathological diagnosis and PET/CT. 4. To receive standard definitive concurrent chemoradiation therapy per NCCN guidelines. 5. Tumor estimated to be within 2cm of heart contour or anticipated MHD\>10Gy per treating physician. Exclusion Criteria: 1. Patients treated with stereotactic body radiotherapy (SBRT). 2. Prior thoracic radiotherapy. Exclusion for Coronary computed tomography angiography (CCTA) 1. History of a severe anaphylactic reaction to iodinated contrast. 2. Renal insufficiency (defined as estimated CrCl less than 30 mL/min). 3. Inability to hold breath for more than 5 seconds. 4. Patients on radioactive iodine therapy. Exclusion for 18F-Flurpiridaz PET/CT Test 1. Second-degree AV block, third-degree AV block, and sinus node disease (such as sick sinus syndrome or symptomatic bradycardia) without a functioning pacemaker. Note: Resting 12-lead EKG will be ordered at the time of enrollment to be performed prior to PET/CT stress test. 2. Patients with bronchospastic diseases including asthma and chronic obstructive pulmonary disease (COPD) who have an acute exacerbation or active wheezing (a high-pitched, musical, adventitious lung sound produced by airflow through the narrowed airways) on the day of PET CT exam. 3. Patients who are hypotensive (systolic blood pressure less than 90 mm Hg) on the day of the PET/CT scan.
References
Publications (0)
Data not yet available
No reference posted for this study.